Yahoo Web Search

Search results

1. • 

     Top Research Reports for Eli Lilly, T-Mobile & BHP

     Zacks via Yahoo Finance· 5 days ago

     Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group...

2. • 

     2024 Innovation Issue: How automation can be a lifesaver - Indianapolis Business Journal

     Indianapolis Business Journal· 5 days ago

     The move is intended to help Lilly meet a crush of demand for its diabetes treatment Mounjaro and...

3. • 

     AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight

     InvestorPlace· 7 hours ago

     The valuation of Amazon (NASDAQ:AMZN) stock is quite attractive while multiple large investors...

4. • Court Rules in Favor of Manufacturers in 340B Drug Shipment Case | JD Supra

     JD Supra· 6 days ago

     On May 21, the U.S. Court of Appeals for the District of Columbia Circuit upheld the right of pharmaceutical manufacturers to place at least some restrictions on the shipment ...

5. • 

     William Blair Commentary: Waistlines and GLP1-s--Expanding in Unison

     GuruFocus.com via Yahoo Finance· 24 hours ago

     Novo Nordisk and Eli Lilly are both developing oral GLP-1 medications for weight loss, which we...

6. • 

     Study Raises Concerns About Rising Cost of Diabetes Meds

     Medscape· 5 days ago

     Driven by payments for diabetes treatments — especially insulin — prescription drugs for metabolic...

7. • Novo Nordisk races to boost Ozempic, Wegovy production

     Becker’s Hospital Review· 6 days ago

     When Ozempic, a Type 2 diabetes drug, and Wegovy, a weight loss therapy recently approved for serious heart problems, quickly rose to fame in late 2022, Denmark-based Novo Nordisk was caught ...

8. • 

     Novo Nordisk’s Race to Produce More of Ozempic’s Secret Sauce

     Bloomberg· 7 days ago

     Have a confidential tip for our reporters? Michael Hallgren, the almost 7-foot-tall Dane tasked with...

9. • Novartis sues Maryland over law prohibiting restrictions on 340B drugs

     Becker’s Hospital Review· 5 days ago

     "Novartis sues Maryland over new law restricting 340B drug pricing program, citing conflict with federal law and potential harm to constitutional rights."

10. • The Newest Side Effect of a Popular Weight Loss Drug

      Mercola· 4 days ago

      Rapid weight loss drugs continue to surge in popularity, making them the major contributor to the 13.5% increase in spending on prescription medications in the U.S. in 2023, according to a report1 ...